Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

被引：4
|
作者：
Ricciuti, B. [1 ]
Genova, C. [2 ]
De Giglio, A. [1 ]
Brambilla, M. [1 ]
Bassanelli, M. [3 ]
Dal Bello, M. G. [2 ]
Baglivo, S. [1 ]
Metro, G. [1 ]
Grossi, F. [4 ]
Chiari, R. [1 ]
机构：
[1] Azienda Osped Perugia, Med Oncol, Santa Maria Della Misericordia Hosp, Perugia, Italy
[2] IRCCS Aou San Martino 1st, Lung Canc Unit, Genoa, Italy
[3] San Camillo de Lellis Hosp, Oncol, Rieti, Italy
[4] IRCCS Aou San Martino 1st, Med Oncol, Genoa, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
non-small cell lung cancer; immune-related adverse events; immune check-point inhibitors;
D O I：
10.1016/j.jtho.2018.08.399
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA10.06
引用
收藏
页码：S390 / S391
页数：2
相关论文
共 50 条
  • [1] Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.
    Ricciuti, Biagio
    De Giglio, Andrea
    Brambilla, Marta
    Bassanelli, Maria
    Metro, Giulio
    Ludovini, Vienna
    Baglivo, Sara
    Chiari, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
    Sato, Koichi
    Akamatsu, Hiroaki
    Murakami, Eriko
    Hayata, Atsushi
    Tokudome, Nahomi
    Akamatsu, Keiichiro
    Koh, Yasuhiro
    Ueda, Hiroki
    Nakanishi, Masanori
    Yamamoto, Nobuyuki
    ANNALS OF ONCOLOGY, 2017, 28 : 86 - 86
  • [3] Correlation Between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated with Nivolumab
    Sato, K.
    Akamatsu, H.
    Eriko, M.
    Sakaki, S.
    Kanai, K.
    Hayata, A.
    Tokudome, N.
    Akamatsu, K.
    Koh, Y.
    Ueda, H.
    Nakanishi, M.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2428 - S2429
  • [4] Association between immune-related adverse events and efficacy of nivolumab in advanced non-small cell lung cancer
    Usui, Yuko
    Udagawa, Hibiki
    Kirita, Keisuke
    Umemura, Shigeki
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Niho, Seiji
    Goto, Koichi
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
    Sato, Koichi
    Akamatsu, Hiroaki
    Murakami, Eriko
    Sasaki, Seigo
    Kanai, Kuninobu
    Hayata, Atsushi
    Tokudome, Nahomi
    Akamatsu, Keiichiro
    Koh, Yasuhiro
    Ueda, Hiroki
    Nakanishi, Masanori
    Yamamoto, Nobuyuki
    LUNG CANCER, 2018, 115 : 71 - 74
  • [6] Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
    Haratani, Koji
    Hayashi, Hidetoshi
    Chiba, Yasutaka
    Kudo, Keita
    Yonesaka, Kimio
    Kato, Ryoji
    Kaneda, Hiroyasu
    Hasegawa, Yoshikazu
    Tanaka, Kaoru
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    JAMA ONCOLOGY, 2018, 4 (03) : 374 - 378
  • [7] Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab
    Kothari, Shawn
    Bagley, Stephen
    Aggarwal, Charu
    Baum, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1290 - S1290
  • [8] Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
    Teraoka, Shunsuke
    Fujimoto, Daichi
    Morimoto, Takeshi
    Kawachi, Hayato
    Ito, Munehiro
    Sato, Yuki
    Nagata, Kazuma
    Nakagawa, Atsushi
    Otsuka, Kojiro
    Uehara, Keiichiro
    Imai, Yukihiro
    Ishida, Kaori
    Fukuoka, Junya
    Tomii, Keisuke
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : 1798 - 1805
  • [9] Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
    Toi, Yukihiro
    Sugawara, Shunichi
    Kawashima, Yosuke
    Aiba, Tomoiki
    Kawana, Sachiko
    Saito, Ryohei
    Tsurumi, Kyoji
    Suzuki, Kana
    Shimizu, Hisashi
    Sugisaka, Jun
    Ono, Hirotaka
    Domeki, Yutaka
    Terayama, Keisuke
    Nakamura, Atsushi
    Yamanda, Shinsuke
    Kimura, Yuichiro
    Honda, Yoshihiro
    ONCOLOGIST, 2018, 23 (11): : 1358 - 1365
  • [10] Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab
    Bouhlel, Linda
    Doyen, Jerome
    Chamorey, Emmanuel
    Poudenx, Michel
    Ilie, Marius
    Gal, Jocelyn
    Guigay, Joel
    Benzaquen, Jonathan
    Marquette, Charles-Hugo
    Berthet, Jean-Philippe
    Mouroux, Jerome
    Schiappa, Renaud
    Padovani, Bernard
    Hofman, Paul
    Otto, Josiane
    BULLETIN DU CANCER, 2020, 107 (09) : 946 - 958
12345